No-one can predict short term movements however price and volume will not get a drug approved by regulators. Statisitical significance in pre-spectied end points is needed, it's very unlikely Annovis have enough to get approved. In a way Annovis mixed results might be helping it in the short term however because it means people speculate more about things like buy out or partnership and Annovis will need one due to having barely any cash.
Market Data 
Markets 
AI
